Literature DB >> 11680595

Activation of cyclin E-dependent kinase activity in colorectal cancer.

W R Cam1, T Masaki, T Y Shiratori, N Kato, M Okamoto, Y Yamaji, K Igarashi, T Sano, M Omata.   

Abstract

Although cyclin E gene amplification is reported to be an important event in various cancers, it is rarely found in human colorectal cancers. As one of the candidate factors of other mechanisms relating to cyclin E, we analyzed cyclin E-dependent kinase activity in colorectal cancer. Protein levels of cyclin E, its catalytic subunit, cyclin-dependent kinase 2 (Cdk2), and p21 and p27 were determined by western blot or immunohistochemistry in 27 colorectal cancers and 10 colorectal adenomas, and compared with adjacent normal colonic mucosa. Enzymatic activity of cyclin E-Cdk2 complex in the colorectal neoplasm was measured using in-gel kinase assay using glutathione S-transferase-retinoblastoma (GST-Rb) fusion protein as substrate, and compared with that of normal mucosa. We clearly showed that although the protein level of cyclin E in colorectal cancer and adenoma was similar to that of adjacent normal mucosa, cylin E-dependent kinase activity was increased in all the cases of colorectal cancers and 90% of colorectal adenomas. The relative kinase activity was significantly higher in colorectal cancer (3.7 +/- 1.7 -fold) than colorectal adenomas (2.0 +/- 0.8-fold) (P < 0.004). The relative expression level of Cdk2 protein in cancer was significantly higher than adenoma (4.4 +/- 2.4 vs 2.7 +/- 1.3, P < 0.04), and p21 and p27 were not detected in colorectal cancer and notably decreased in adenoma. The results of this study strongly suggest that activation of cyclin E-dependent kinase activity may play an important role in colorectal cancer, and its level appears to be related to increased Cdk2 and decreased p21 and p27 amounts rather than cyclin E protein level.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11680595     DOI: 10.1023/a:1011962915280

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  46 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  Cyclin E dependent kinase activity in human breast cancer in relation to cyclin E, p27 and p21 expression and retinoblastoma protein phosphorylation.

Authors:  M Lodén; N H Nielsen; G Roos; S O Emdin; G Landberg
Journal:  Oncogene       Date:  1999-04-22       Impact factor: 9.867

3.  The adenovirus E1A-associated kinase consists of cyclin E-p33cdk2 and cyclin A-p33cdk2.

Authors:  B Faha; E Harlow; E Lees
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

4.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Regulation of retinoblastoma protein functions by ectopic expression of human cyclins.

Authors:  P W Hinds; S Mittnacht; V Dulic; A Arnold; S I Reed; R A Weinberg
Journal:  Cell       Date:  1992-09-18       Impact factor: 41.582

6.  Formation and activation of a cyclin E-cdk2 complex during the G1 phase of the human cell cycle.

Authors:  A Koff; A Giordano; D Desai; K Yamashita; J W Harper; S Elledge; T Nishimoto; D O Morgan; B R Franza; J M Roberts
Journal:  Science       Date:  1992-09-18       Impact factor: 47.728

7.  Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases.

Authors:  Y Geng; R A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

8.  CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle.

Authors:  S J Elledge; R Richman; F L Hall; R T Williams; N Lodgson; J W Harper
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

9.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

10.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family.

Authors:  A Koff; F Cross; A Fisher; J Schumacher; K Leguellec; M Philippe; J M Roberts
Journal:  Cell       Date:  1991-09-20       Impact factor: 41.582

View more
  10 in total

1.  Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability.

Authors:  W Jiang; H Huang; L Ding; P Zhu; H Saiyin; G Ji; J Zuo; D Han; Y Pan; D Ding; X Ma; Y Zhang; J Wu; Q Yi; J O Liu; H Huang; Y Dang; L Yu
Journal:  Oncogene       Date:  2014-11-17       Impact factor: 9.867

2.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

3.  Curcumin suppresses proliferation of colon cancer cells by targeting CDK2.

Authors:  Tae-Gyu Lim; Sung-Young Lee; Zunnan Huang; Do Young Lim; Hanyong Chen; Sung Keun Jung; Ann M Bode; Ki Won Lee; Zigang Dong
Journal:  Cancer Prev Res (Phila)       Date:  2014-02-18

4.  Cold-inducible RNA-binding protein contributes to human antigen R and cyclin E1 deregulation in breast cancer.

Authors:  Xun Guo; Yuehan Wu; Rebecca S Hartley
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

5.  Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression.

Authors:  Hannah Wingate; Agnes Puskas; Mylinh Duong; Tuyen Bui; Dana Richardson; Yanna Liu; Susan L Tucker; Carolyn Van Pelt; Laurent Meijer; Kelly Hunt; Khandan Keyomarsi
Journal:  Cell Cycle       Date:  2009-04-10       Impact factor: 4.534

6.  Attenuated expression of HRH4 in colorectal carcinomas: a potential influence on tumor growth and progression.

Authors:  Zhengyu Fang; Wantong Yao; Yi Xiong; Jiana Li; Li Liu; Lei Shi; Wei Zhang; Chao Zhang; Liping Nie; Jun Wan
Journal:  BMC Cancer       Date:  2011-05-24       Impact factor: 4.430

7.  NF90 stabilizes cyclin E1 mRNA through phosphorylation of NF90-Ser382 by CDK2.

Authors:  Donglin Ding; Huixing Huang; Quanfu Li; Wenbo Yu; Chenji Wang; Haijie Ma; Jiaxue Wu; Yongjun Dang; Long Yu; Wei Jiang
Journal:  Cell Death Discov       Date:  2020-01-22

8.  Development of newly synthesised quinazolinone-based CDK2 inhibitors with potent efficacy against melanoma.

Authors:  Eman R Mohammed; Ghada F Elmasry
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

9.  Synthesis and Evaluation of Some New 4H-Pyran Derivatives as Antioxidant, Antibacterial and Anti-HCT-116 Cells of CRC, with Molecular Docking, Antiproliferative, Apoptotic and ADME Investigations.

Authors:  Nahed N E El-Sayed; Magdi E A Zaki; Sami A Al-Hussain; Abir Ben Bacha; Malika Berredjem; Vijay H Masand; Zainab M Almarhoon; Hanaa S Omar
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-19

10.  A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer.

Authors:  Xinkui Liu; Jiarui Wu; Dan Zhang; Kaihuan Wang; Xiaojiao Duan; Xiaomeng Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2018-02-12       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.